Download View NIH Biographical Sketch as a PDF - Cedars

Contact Program Director/Principal Investigator (Last, First, Middle):
Wolmark, Norman, MD et al.
BIOGRAPHICAL SKETCH
Provide the following information for the key personnel in the order listed for Form Page 2.
Follow the sample format on preceding page for each person. DO NOT EXCEED FOUR PAGES.
NAME
POSITION TITLE
Sandler, Howard M.
Professor and Chairman of Radiation Oncology
EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing,
and include postdoctoral training.)
INSTITUTION AND LOCATION
University of Connecticut
University of Connecticut
University of Connecticut
DEGREE
(if applicable)
B.S.
M.D.
M.S.
YEAR(s)
FIELD OF STUDY
1978 Physics
1985 Medicine
1991 Physics
A. Personal Statement
Cooperative group cancer research has been a cornerstone in the validation of novel strategies in the
management of cancer patients. My role within this research project as chair of the Genitourinary Cancer
Committee is to develop clinical trials to enhance the care of patients with genitourinary malignancies. While
we tend to focus on phase III trials, the committee is also developing earlier phase treatments plus using an
extensive and well-annotated tissue repository along with latest-generation sequencing techniques to
implement an individualized approach to future therapeutic strategies. As current chairman of the RTOG
Genitourinary Cancer Committee, the committee is excited about the future of clinical and translation research
in the area of genitourinary cancers.
B.
Positions and Honors
Positions and Employment
1985-1986
Internship: Medicine, St. Francis Hospital and Medical Center, Hartford, CT
1986-1989
Residency: Department of Radiation Oncology, Hospital of the University of Pennsylvania,
Philadelphia, PA
1988-1989
Chief Resident: Department of Radiation Oncology, Hospital of the University of
Pennsylvania, Philadelphia, PA
1989-1995
Assistant Professor: Department of Radiation Oncology, University of Michigan
1995-2001
Associate Professor with Tenure
2001-2008
Professor
2003-2008
Senior Associate Chair
2007-2008
Newman Family Professor of Radiation Oncology
2008Professor and Chair, Department of Radiation Oncology, Cedars-Sinai Medical Center
2009Ronald H. Bloom Family Chair in Cancer Therapeutics
1997Chair, RTOG (now NRG) Genitourinary Committee
Other Experience and Professional Memberships
American Society of Therapeutic Radiology and Oncology
American Society of Clinical Oncology
NRG Oncology (previously Radiation Therapy Oncology Group)
Southwest Oncology Group
Society of Urologic Oncology
C.
Recent Publications (from 208 total publications)
PHS 398/2590 (Rev. 06/09)
Biographical Sketch Format Page
Contact Program Director/Principal Investigator (Last, First, Middle):
Wolmark, Norman, MD et al.
1.
Khor LY, Bae K, Pollack A, Hammond ME, Grignon DJ, Venkatesan VM, Rosenthal SA, Ritter MA,
Sandler HM, Hanks GE, Shipley WU, Dicker AP. COX-2 expression predicts prostate-cancer outcome:
analysis of data from the RTOG 92-02 trial. Lancet Oncol 8:912-920, 2007.
2.
Efstathiou JA, Bae K, Shipley WU, Hanks GE, Pilepich MV, Sandler HM, Smith MR: Obesity and
prostate cancer-specific mortality following radiation therapy and androgen suppression for locally advanced
prostate cancer: An analysis of RTOG 85-31. Cancer 110:2691-2699, 2007.
3.
Sanda MG, Dunn RL, Michalski J, Sandler HM, Northouse L, Hembroff L, Lin X, Greenfield TK, Litwin
MS, Saigal CS, Mahadevan A, Klein E, Kibel A, Pisters L, Kuban D, Kaplan I, Wood D, Ciezki J, Shah N, Wei
JT: HRQOL and satisfaction with cancer treatment outcome from the perspective of early stage prostate
cancer patients and their spouse/partners. NEJM 358:1250-1261, 2008.
4.
Lee IH, Sadetsky N, Carroll P, Sandler HM: The impact of treatment choice for localized prostate
cancer on response to phosphodiesterase inhibitors. J Urol 179:1072-1076, 2008.
5.
Horwitz EM, Bae K, Hanks GE, Porter A, Grignon DJ, Brereton H, Venkatesan V, Lawton CA,
Rosenthal SA, Sandler HM, Shipley WU: Ten-Year Follow-Up Of RTOG 92-02: A phase III trial of the duration
of elective androgen deprivation in locally advanced prostate cancer. JCO 26:2497-2504, 2008.
6.
Spencer BA, Miller DC, Litwin MS, Ritchey JD, Stewart AK, Dunn RL, Gay EG, Sandler HM, Wei JT.
Variations in quality of care for men with early-stage prostate cancer. JCO 26:3735-3742, 2008.
7.
Khor L-Y, Bae K, DeSilvio M, Al-Saleem T, Hammond MEH, Grignon DJ, Sause WT, Pilepich MV,
Okunieff P, Sandler HM, Pollack A: Protein kinase A RI-alpha (PKA-RIa) predicts prostate cancer outcome: An
analysis of Radiation Therapy Oncology Group Trial 86-10. Int J Radiat Oncol Biol Phys 71:1309-1315, 2008.
8.
Smith MR, Bae K, Efstathiou JA, Hanks GE, Pilepich MV, Sandler HM, Shipley WU: Diabetes and
mortality in men with locally advanced prostate cancer: Analyses of Radiation Therapy Oncology Group
(RTOG) Protocol 92-02. JCO 26:4333-4339, 2008.
9.
Efstathiou JA, Bae K, Shipley WU, Hanks GE, Pilepich MV, Sandler HM, Smith MR. Cardiovascular
mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31. JCO 27:92-99,
2009.
10.
Souhami L, Bae K, Pilepich M, Sandler H: Impact of the duration of adjuvant hormonal therapy in
patients with locally advanced prostate cancer treated with radiotherapy: a secondary analysis of RTOG 85-31.
J Clin Oncol 27:2137-2143, 2009.
11.
Michalski JM, Bae K, Roach M, Markoe AM, Sandler HM, Ryu J, Parliament MB, Straube W, Valicenti
RK, Cox JD: Long-term toxicity following 3D conformal radiation therapy for prostate cancer from the RTOG
9406 phase I/II dose escalation study. Int J Radiat Oncol Biol Phys 76:14-22, 2010.
12.
Thames HD, Kuban D, Levy LB, Horwitz EM, Kupelian P, Martinez A, Michalski J, Pisansky T, Sandler
H, Shipley W, Zelefsky M, Zietman A: The role of overall treatment time in the outcome of radiotherapy of
prostate cancer: An analysis of biochemical failure in 4839 men treated by external beam radiotherapy
between 1987 and 1995. Radiother Oncol 96:6-12, 2010.
13.
Sandler HM, Liu P-Y, Dunn RL, Khan DC, Tropper SE, Sanda MG, Mantz CA: Reduction in patientreported acute morbidity in prostate cancer patients treated with 81 Gy IMRT using reduced PTV margins and
electromagnetic tracking: Assessing the impact of margin reduction (AIM) study. Urology 75:1004-1008, 2010.
PHS 398/2590 (Rev. 06/09)
Biographical Sketch Format Page
Contact Program Director/Principal Investigator (Last, First, Middle):
Wolmark, Norman, MD et al.
14.
Jones CU, Hunt D, McGowan DG, Amin MB, Chetner MP, Bruner DW, Liebenhaut MH, Husain SM,
Rotman M, Souhami L, Sandler HM, Shipley WU: Radiotherapy and short-term androgen deprivation for
localized prostate cancer. NEJM 365:107-118, 2011.
15.
Alemozaffar M, Regan MM, Cooperberg MR, Wei JT, Michalski JM, Sandler HM, Hembroff L, Sadetsy
N, Saigal CS, Litwin MS, Klein E, Kibel AS, Hamstra DA, Pisters LL, Kuban DA, Kaplan ID, Wood DP, Ciezki J,
Dunn RL, Carroll PR, Sanda MG. Prediction of erectile function following treatment for prostate cancer. JAMA
306:1205-14, 2011.
16.
Feng FA, Qian Y, Stenmark MH, Halverson S, Blas K, Vance S, Sandler HM, Hamstra DA, Perineural
invasion predicts increased recurrence, metastasis, and death from prostate cancer following treatment with
dose-escalated radiation therapy. Int J Radiat Oncol Biol Phys 81:361-367, 2011.
17.
Halverson S, Schipper M, Blas K, Lee V, Sabolch A, Olson K, Sandler HM, Feng FY, Hamstra DA: The
Cancer of the Prostate Risk Assessment (CAPRA) in patients treated with external beam radiation therapy:
Evaluation and optimization in patients at higher risk of relapse. Radiother Oncol 101:513-520, 2011.
18. Soto DE, Passarelli MN, Daignault S, Sandler HM. Concurrent androgen deprivation therapy during
salvage prostate radiotherapy improves treatment outcomes in high-risk patients. Int J Radiat Oncol Biol Phys
82:1227-1232, 2012.
19.
Kapadia NS, Olson K, Sandler HM, Feng FY, Hamstra DA: Interval to biochemical failure as a
biomarker for cause-specific and overall survival after dose-escalated external beam radiation therapy for
prostate cancer. Cancer 118:2059-2068, 2012.
20.
Hamstra D, Conlon AS, Daignault S, Dunn RL, Sandler HM, Hembroff LA, Zietman AL, Kaplan I, Cieski
J, Kuban D, Wei J, Sanda MG, Michalski J: Multi-institutional prospective evaluation of bowel quality of life
after prostate external beam radiation therapy identifies patient and treatment factors associated with patient
reported outcomes: The PROSTQA experience. Int J Radiat Oncol Biol Phys 86:546-553, 2013. PMID:
23561651.
21.
Feng F, Blas K, Olson K, Stenmark M, Sandler H, Hamstra D: Retrospective evaluation reveals that
long-term androgen deprivation therapy improves cause-specific and overall survival in the setting of doseescalated radiation for high-risk prostate cancer. Int J Radiat Oncol Biol Phys 86:64-71, 2013. PMID:
23462420.
22.
Kazer MW, Bailey DE, Chipman J, Psutka SP, Hardy J, Hembroff L, Regan M, Dunn R, Crociani C,
Sanda MG, PROSTQA Consortium Study Group: Uncertainty and danger among survivors of prostate cancer
treatment. BJU Int 111:E84-91, 2013.
23.
Mitin T, Hunt D, Shipley WU, Kaufman DS, Uzzo R, Wu CL, Buyyounouski MK, Sandler H, Zietman AL.
Transurethral surgery and twice-daily radiation plus paclitaxel-cisplatin or fluorouracil-cisplatin with selective
bladder preservation and adjuvant chemotherapy for patients with muscle invasive bladder cancer (RTOG
0233): a randomised multicentre phase 2 trial. Lancet Oncol 14:863-872, 2013. PMID: 23823157.
24.
Gilbert SM, Sanda MG, Dunn RL, Greenfield T, Hembroff L, Klein E, Saigal C, Pisters L, Michalski J,
Sandler HM, Litwin MS, Shah N, Wei JT: Satisfaction with information used to choose prostate cancer
treatment. J Urol Epub Dec 11, 2013. PMID: 24333514.
25.
Efstathiou JA, Nassif DS, McNutt TR, Bogardus CB, Bosch W, Carlin J, Chen RC, Chou H, Eggert D,
Fraass BA, Goldwein J, Hoffman KE, Hotz K, Hunt M, Kessler M, Lawton CA, Mayo C, Michalski JM, Mutic S,
Potters L, Rose CM, Sandler HM, Sharp G, Tomé W, Tran PT, Wall T, Zietman AL, Gabriel PE, Bekelman JE.
Practice-based evidence to evidence-based practice: building the National Radiation Oncology Registry. J
Oncol Pract 9:e90-5, 2013 PMID: 23942508.
PHS 398/2590 (Rev. 06/09)
Biographical Sketch Format Page
Contact Program Director/Principal Investigator (Last, First, Middle):
Wolmark, Norman, MD et al.
26.
Parker C, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, Fosså SD, Chodacki A, Wiechno P, Logue J,
Seke M, Widmark A, Johannessen DC, Hoskin P, Bottomley D, James ND, Solberg A, Syndikus I, Kliment J,
Wedel S, Boehmer S, Dall'Oglio M, Franzén L, Coleman R, Vogelzang NJ, O'Bryan-Tear CG, Staudacher K,
Garcia-Vargas J, Shan M, Bruland ØS, Sartor O; ALSYMPCA Investigators. Alpha emitter radium-223 and
survival in metastatic prostate cancer. N Engl J Med 369:213-23, 2013. PMID: 23863050. (Sandler was one of
the ALSYMPCA investigators)
27.
Hoppe BS, Michalski JM, Mendenhall NP, Morris CG, Henderson RH, Nichols RC, Mendenhall WM,
Williams CR, Regan MM, Chipman JJ, Crociani CM, Sandler HM, Sanda MG, Hamstra DA.Comparative
effectiveness study of patient-reported outcomes following proton therapy or IMRT for definitive treatment of
prostate cancer. Cancer 120:1076-1082, 2014. PMID: 24382757.
28.
Jarow JP, Thompson IM, Kluetz PG, Baxley J, Sridhara R, Scardino P, Carroll P, Albertsen P, Carter
HB, Brawley O, Sartor O, Sandler H, Kiefert JJ, Morton RA Jr: Drug and Device Development for Localized
Prostate Cancer: Report of a Food and Drug Administration/American Urological Association Public Workshop.
Urology Epub 2014. PMID: 24661332.
D.
Research Support
Ongoing Research Support
U10 CA021661 NIH/NCI (Curran)
01/01/09 – 12/31/14
This project is to lead the Genitourinary Cancer Committee of RTOG-NRG. Responsibilities are to develop and
lead practice-changing clinical trials in the management of genitourinary cancers.
Role: RTOG-NRG Genitourinary Cancer Committee Chair.
Completed Research Support
None
PHS 398/2590 (Rev. 06/09)
Biographical Sketch Format Page